Montelukast Sodium Market: How Are Neuropsychiatric Safety Concerns Reshaping Prescribing Practices?
The Montelukast Sodium Market in 2026 has been materially affected by the FDA's March 2020 addition of a black box warning for serious neuropsychiatric adverse events to all montelukast formulations, representing the strongest warning the FDA can require on prescription drug labeling and signaling the agency's assessment that the neuropsychiatric risk is serious enough to potentially outweigh...
0 Commentarios 0 Acciones 54 Views 0 Vista previa